Current Status and Perspectives of Tyrosine Kinase Inhibitor Treatment in the Posttransplant Period in Patients with Chronic Myelogenous Leukemia (CML)

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 3, 2010, Pages 301-310

  Klyuchnikov, Evgeny ^a   Kröger, Nicolaus ^a   Brummendorf, Tim H ^a   Wiedemann, Bettina ^a   Zander, Axel Rolf ^a   Bacher, Ulrike ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Allogeneic stem cell transplantation (SCT); Chronic myelogenous leukemia (CML); Dasatinib; Imatinib; Tyrosine kinase inhibitors (TKIs)

Indexed keywords

BCR ABL PROTEIN; CALCINEURIN INHIBITOR; DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; TRIAZOLE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; ALLOGENEIC STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER PREVENTION; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DONOR LYMPHOCYTE INFUSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; IMMUNOMODULATION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER DYSFUNCTION; LIVER TOXICITY; LUNG DISEASE; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; NONHUMAN; PANCYTOPENIA; PERIORBITAL EDEMA; POLYMERASE CHAIN REACTION; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; STEM CELL TRANSPLANTATION;

EID: 75749095531     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.08.019     Document Type: Review

References (65)

1. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 (2001) 1031-1037
2. Gambacorti-Passerini C., le Coutre P., Mologni L., et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 23 (1997) 380-394
3. Le Coutre P., Mologni L., Cleris L., et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 91 (1999) 163-168
4. Gratwohl A., Brand R., Apperley J., et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 91 (2006) 513-521
5. Jabbour E., Cortes J., Kantarjian H.M., et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 108 (2006) 1421-1423
6. Bacher U., Klyuchnikov E., Zabelina T., et al. The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia-a report from the German Registry covering the period from 1998 to 2004. Ann Hematol (March 2009) [Epub ahead of print]
7. Kantarjian H.M., O'Brien S., Cortes J.E., et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 100 (2002) 1590-1595
8. DeAngelo D.J., Hochberg E.P., Alyea E.P., et al. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res 10 (2004) 5065-5071
9. Olavarria E., Ottmann O.G., Deininger M., et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 17 (2003) 1707-1712
10. Carpenter P.A., Snyder D.S., Flowers M.E., et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 109 (2007) 2791-2793
11. Palandri F., Amabile M., Rosti G., et al. Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. Bone Marrow Transplant 39 (2007) 189-191
12. Atallah E., Kantarjian H., De Lima M., et al. The role of dasatinib in patients with Philadelphia (Ph) positive acute lymphocytic leukemia (ALL) and chronic myeloid leukemia (CML) relapsing after stem cell transplantation (SCT). Blood 108 (2006) 4520
13. Klyuchnikov E., Schafhausen P., Kroger N., et al. Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. Acta Haematol 122 (2009) 6-10
14. Hess G., Bunjes D., Siegert W., et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol 23 (2005) 7583-7593
15. Rousselot P., Huguet F., Rea D., et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109 (2007) 58-60
16. Olavarria E., Siddique S., Griffiths M.J., et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood 110 (2007) 4614-4617
17. Savani B.N., Montero A., Kurlander R., et al. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant 36 (2005) 1009-1015
18. Appel S., Balabanov S., Brummendorf T.H., et al. Effects of imatinib on normal hematopoiesis and immune activation. Stem Cells 23 (2005) 1082-1088
19. Appel S., Boehmler A.M., Grunebach F., et al. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood 103 (2004) 538-544
20. Taieb J., Maruyama K., Borg C., et al. Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo. Blood 103 (2004) 1966-1967
21. Boissel N., Rousselot P., Raffoux E., et al. Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate. Leukemia 18 (2004) 1656-1661
22. Dewar A.L., Doherty K.V., Hughes T.P., et al. Imatinib inhibits the functional capacity of cultured human monocytes. Immunol Cell Biol 83 (2005) 48-56
23. Cwynarski K., Laylor R., Macchiarulo E., et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 18 (2004) 1332-1339
24. Leder C., Ortler S., Seggewiss R., et al. Modulation of T-effector function by imatinib at the level of cytokine secretion. Exp Hematol 35 (2007) 1266-1271
25. Dietz A.B., Souan L., Knutson G.J., et al. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 104 (2004) 1094-1099
26. Kantarjian H., Talpaz M., O'Brien S., et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103 (2004) 2873-2878
27. Rea D., Legros L., Raffoux E., et al. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia 20 (2006) 400-403
28. Mattiuzzi G.N., Cortes J.E., Talpaz M., et al. Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res 9 (2003) 976-980
29. Ikeda K., Shiga Y., Takahashi A., et al. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma 47 (2006) 155-157
30. Lin J.T., Lee M.Y., Hsiao L.T., et al. Pulmonary nocardiosis in a patient with CML relapse undergoing imatinib therapy after bone marrow transplantation. Ann Hematol 83 (2004) 444-446
31. Mumprecht S., Matter M., Pavelic V., et al. Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. Blood 108 (2006) 3406-3413
32. Sinai P., Berg R.E., Haynie J.M., et al. Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in vivo. J Immunol 178 (2007) 2028-2037
33. Bocchia M., Gentili S., Abruzzese E., et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 365 (2005) 657-662
34. Bocchia M., Abruzzese E., Forconi F., et al. Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia. Leukemia 20 (2006) 142-143
35. Burke M.J., Trotz B., Luo X., et al. Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival. Bone Marrow Transplant 43 (2009) 107-113
36. Larmonier N., Janikashvili N., LaCasse C.J., et al. Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors. J Immunol 181 (2008) 6955-6963
37. Magro L., Catteau B., Coiteux V., et al. Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD. Bone Marrow Transplant 42 (2008) 757-760
38. Branford S., Rudzki Z., Walsh S., et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102 (2003) 276-283
39. Jabbour E., Kantarjian H., Jones D., et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20 (2006) 1767-1773
40. Soverini S., Colarossi S., Gnani A., et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 12 (2006) 7374-7379
41. Hochhaus A., and La R.P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 18 (2004) 1321-1331
42. Kantarjian H., Pasquini R., Hamerschlak N., et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 109 (2007) 5143-5150
43. O'Hare T., Walters D.K., Stoffregen E.P., et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65 (2005) 4500-4505
44. Weisberg E., Manley P.W., Breitenstein W., et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7 (2005) 129-141
45. Tanaka R., and Kimura S. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation. Expert Rev Anticancer Ther 8 (2008) 1387-1398
46. Aichberger K.J., Herndlhofer S., Agis H., et al. Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy. Eur J Clin Invest 37 (2007) 808-813
47. Altintas A., Cil T., Kilinc I., et al. Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report. J Neurooncol 84 (2007) 103-105
48. Petzer A.L., Gunsilius E., Hayes M., et al. Low concentrations of STI571 in the cerebrospinal fluid: a case report. Br J Haematol 117 (2002) 623-625
49. Ocheni S., Iwanski G.B., Schafhausen P., et al. Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation. Leuk Lymphoma 50 (2009) 551-558
50. Porkka K., Koskenvesa P., Lundan T., et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 112 (2008) 1005-1012
51. Hughes T., Deininger M., Hochhaus A., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108 (2006) 28-37
52. Baccarani M., Pane F., and Saglio G. Monitoring treatment of chronic myeloid leukemia. Haematologica 93 (2008) 161-169
53. Baccarani M., Saglio G., Goldman J., et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108 (2006) 1809-1820
54. Kantarjian H., Schiffer C., Jones D., et al. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 111 (2008) 1774-1780
55. Kaeda J., O'Shea D., Szydlo R.M., et al. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood 107 (2006) 4171-4176
56. Kolb H.J., Mittermuller J., Clemm C., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76 (1990) 2462-2465
57. Porter D.L., Roth M.S., McGarigle C., et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330 (1994) 100-106
58. Kolb H.J., Schattenberg A., Goldman J.M., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86 (1995) 2041-2050
59. Collins Jr. R.H., Shpilberg O., Drobyski W.R., et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15 (1997) 433-444
60. Michallet A.S., Nicolini F., Furst S., et al. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT). Bone Marrow Transplant 35 (2005) 601-608
61. Weisser M., Tischer J., Schnittger S., et al. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica 91 (2006) 663-666
62. Mackinnon S., Papadopoulos E.B., Carabasi M.H., et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86 (1995) 1261-1268
63. Deininger M., Schleuning M., Greinix H., et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica 91 (2006) 452-459
64. Oehler V.G., Gooley T., Snyder D.S., et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 109 (2007) 1782-1789
65. Gontarewicz A., Balabanov S., Keller G., et al. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 111 (2008) 4355-4364